TNFRSF1A and neoplasm: In the viral cytokine receptor pathway, upregulated genes (p = 1.39 × 10−5), including TNFRSF1A, CCL21, IL2RB, IL22RA1, and XCR1, suggest that oncolytic viruses exploit tumor-specific immune evasion mechanisms to selectively lyse tumor cells, activating anti-tumor immunity via DAMPs and PAMPs (30).